1.41 0.11 (8.46%) | 02-12 19:59 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 1.91 ![]() |
1-year : | 2.17 ![]() |
Resists | First : | 1.63 ![]() |
Second : | 1.86 ![]() |
Pivot price | 1.48 ![]() |
|||
Supports | First : | 1.27 | Second : | 1.06 |
MAs | MA(5) : | 1.38 ![]() |
MA(20) : | 1.49 ![]() |
MA(100) : | 1.53 ![]() |
MA(250) : | 1.42 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 16.3 ![]() |
D(3) : | 12.5 ![]() |
RSI | RSI(14): 40.8 ![]() |
|||
52-week | High : | 3.01 | Low : | 0.8 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ITRM ] has closed above bottom band by 27.0%. Bollinger Bands are 51.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 1.42 - 1.43 | 1.43 - 1.44 |
Low: | 1.27 - 1.28 | 1.28 - 1.29 |
Close: | 1.39 - 1.41 | 1.41 - 1.42 |
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Sat, 08 Feb 2025
Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance
Fri, 07 Feb 2025
Iterum Therapeutics Highlights FDA Approval and Financial Progress - TipRanks
Fri, 07 Feb 2025
Earnings call transcript: Iterum Therapeutics reports Q4 2024 results and stock surges - MSN
Fri, 07 Feb 2025
Iterum Therapeutics PLC Files For Mixed Shelf Of Up To $150 Million -February 07, 2025 at 04:42 pm EST - Marketscreener.com
Fri, 07 Feb 2025
Iterum Therapeutics PLC reports results for the quarter ended December 31 - Earnings Summary - TradingView
Fri, 07 Feb 2025
Iterum Therapeutics plc (ITRM) reports earnings - Quartz
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 28 (M) |
Shares Float | 22 (M) |
Held by Insiders | 1.8 (%) |
Held by Institutions | 8.9 (%) |
Shares Short | 2,530 (K) |
Shares Short P.Month | 215 (K) |
EPS | -1.76 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -0.47 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -73.4 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -1.36 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -42 (M) |
Levered Free Cash Flow | -28 (M) |
PE Ratio | -0.81 |
PEG Ratio | 0 |
Price to Book value | -3 |
Price to Sales | 0 |
Price to Cash Flow | -0.93 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |